Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 2Genitourinary 2Breast 2Sarcoma 1Other 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 728Paclitaxel 694Cyclophosphamide 647Docetaxel 559Capecitabine 485Letrozole 437Fulvestrant 398Carboplatin 397Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 272exemestane 258Epirubicin 251Radiotherapy 239pertuzumab 237palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 151Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Surgical Instruments × Breast × Clear all
NCT06294574 2025-09-22

Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction

University of Alabama at Birmingham

Phase NA Recruiting
150 enrolled
Breast

Breast Neoplasms

NCT05173415 2025-02-24

MALLORCA

Brust-Zentrum AG

Phase NA Completed
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡